Study of INCB086550 in Select Solid Tumors
About the study
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Non Small Cell Lung Cancer,Urothelial Cancer,Renal Cell Carcinoma,Hepatocellular Carcinoma,Melanoma
Age (in years)
18+
Phase
Phase 2
Participants needed
16
Est. Completion Date
Aug 20, 2024
Treatment type
Interventional
Sponsor
Incyte Corporation
ClinicalTrials.gov identifier
NCT04629339
Study number
INCB 86550-203
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?